Neuroblastoma mRNAs Predict Outcome in Children With Stage 4 Neuroblastoma: AEuropean HR-NBL1/SIOPEN Study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10292992" target="_blank" >RIV/00064203:_____/14:10292992 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/14:10292992
Result on the web
<a href="http://dx.doi.org/10.1200/JCO.2013.53.3604" target="_blank" >http://dx.doi.org/10.1200/JCO.2013.53.3604</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1200/JCO.2013.53.3604" target="_blank" >10.1200/JCO.2013.53.3604</a>
Alternative languages
Result language
angličtina
Original language name
Neuroblastoma mRNAs Predict Outcome in Children With Stage 4 Neuroblastoma: AEuropean HR-NBL1/SIOPEN Study
Original language description
Purpose To evaluate the hypothesis that detection of neuroblastoma mRNAs by reverse transcriptase quantitative polymerase chain reaction (RTqPCR) in peripheral blood (PB) and bone marrow aspirates (BM) from children with stage 4 neuroblastoma are clinically useful biomarkers of risk. Methods RTqPCR for paired-like homeobox 2b (PHOX2B), tyrosine hydroxylase (TH), and doublecortin (DCX) mRNA in PB and BM of children enrolled onto the High-Risk Neuroblastoma Trial-1 of the European Society of Pediatric Oncology Neuroblastoma Group (HR-NBL1/SIOPEN) was performed at diagnosis and after induction therapy. Results High levels of TH, PHOX2B, or DCX mRNA in PB or BM at diagnosis strongly predicted for worse event-free survival (EFS) and overall survival (OS) ina cohort of 290 children. After induction therapy, high levels of these mRNAs predicted worse EFS and OS in BM but not in PB. Combinations of mRNAs in BM did not add to the predictive power of any single mRNA. However, in the original (n
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Clinical Oncology
ISSN
0732-183X
e-ISSN
—
Volume of the periodical
32
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
1074-1083
UT code for WoS article
000335138400017
EID of the result in the Scopus database
—